Search

Displaying results 5181 - 5190 of 6835 in total
  1. Drug

    Zotiraciclib

    go.drugbank.com/drugs/DB16656
    Investigational

    Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide

  2. Drug

    EW-A-401

    go.drugbank.com/drugs/DB05525
    Investigational

    This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels. … EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes.

  3. Drug

    Polaprezinc

    go.drugbank.com/drugs/DB09221
    Investigational

    It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].

  4. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  5. Drug

    BMS-986141

    go.drugbank.com/drugs/DB14942
    Investigational

    BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).

  6. Drug

    V116517

    go.drugbank.com/drugs/DB16060
    Investigational

    V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).

  7. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  8. Drug

    SB-269970

    go.drugbank.com/drugs/DB13988
    Experimental

    SB-269970 is an experimental drug developed by GlaxoSmithKline.

  9. Drug

    Prostaglandin D2

    go.drugbank.com/drugs/DB02056
    Experimental

    It is released upon activation of mast cells and is also synthesized by alveolar macrophages.

  10. Drug

    NSI-566

    go.drugbank.com/drugs/DB17954
    Investigational

    Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]